Mineralys Therapeutics
在场
高管
查看带有其 19 名主要高管的组织结构图
Mineralys Therapeutics 搜索最多的简介
高管在Mineralys Therapeutics变化
- Stephen Djedjos, Senior Vice President, Clinical Development, 已经离开公司 (新闻发布的2025一月24号).
- Alexander Gold已作为Director加入公司 (新闻发布的2024六月16号).
创建提醒
跟踪 Mineralys Therapeutics 的高管变动
生物技术
Mineralys Therapeutics 拥有 2,347 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Bristol-Myers Squibb has announced the acquisition of 2Seventy Bio (公布2025三月11号).
- Callio Therapeutics 刚刚宣布为 187 筹款数百万美元。 (公布2025三月7号).
- Eikon Therapeutics 刚刚宣布为 351 筹款数百万美元。 (公布2025二月27号).
生物技术 行业的其他推荐联系人
消息
Mineralys Therapeutics 的最新新闻稿
- Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
- Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
- Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
- Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Mineralys Therapeutics to Participate in Upcoming Investor Conferences
- Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
- Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
- Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
- Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
- View more press releases Close
